Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exenatide - Intarcia Therapeutics

Drug Profile

Exenatide - Intarcia Therapeutics

Alternative Names: Exenatide in DUROS®; Exenatide intravenous - Intarcia Therapeutics; Exenatide subcutaneous implant - Intarcia Therapeutics; Exendin-4; ITCA-650

Latest Information Update: 18 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intarcia Therapeutics
  • Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Type 2 diabetes mellitus

Highest Development Phases

  • Preregistration Type 2 diabetes mellitus

Most Recent Events

  • 18 Dec 2018 Intarcia announces intention to resubmit NDA to USFDA for Type 2 diabetes mellitus in mid-2019
  • 01 Oct 2018 Safety and efficacy data from the phase III FREEDOM-3S trial for Type-2 diabetes mellitus presented at 54th Annual Meeting of the European Association for the Study of Diabetes (EASD-2018)
  • 19 Feb 2018 NCT01785771 (triggered from news on Intarcia) - Added recruitment termination info
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top